


# 340B Program Growing at Double-Digit Rates

## TOTAL PURCHASES MADE UNDER THE 340B DRUG PRICING PROGRAM

■ Purchases at discounted 340B prices

■ Estimated purchases at invoice prices

**340B program: 22.8% per year**  
**Manufacturers' net revenues: 5.1% per year**



Source: Drug Channels Institute analysis of data from Health Resources and Services Administration and IQVIA. Dollar figures in billions. Excludes sales made directly to healthcare institutions by manufacturers. Data for purchases at discounted prices show value of purchases at or below the discounted 340B ceiling prices. Data at invoice prices reflect DCI estimates. Growth rates show compound average growth rate.

Published on Drug Channels ([www.DrugChannels.net](http://www.DrugChannels.net)) on May 7, 2018.